Healthcare provider profile · identity verified

Gary D. Stebelton, M.D.

Internal Medicine · GRAND RAPIDS, MI · NPI 1215966957

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	421	129
Levothyroxine Sodium	Levothyroxine Sodium	357	94
Omeprazole	Omeprazole	326	97
Lisinopril	Lisinopril	300	89
Losartan Potassium	Losartan Potassium	238	66
Metformin Hcl	Metformin Hcl	237	62
Simvastatin	Simvastatin	194	49
Amlodipine Besylate	Amlodipine Besylate	185	59
Tamsulosin Hcl	Tamsulosin Hcl	160	52
Pravastatin Sodium	Pravastatin Sodium	147	41
Hydrochlorothiazide	Hydrochlorothiazide	144	38
Metformin Hcl Er	Metformin Hcl	125	39
Metoprolol Succinate	Metoprolol Succinate	117	37
Pantoprazole Sodium	Pantoprazole Sodium	112	34
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	106	30
Rosuvastatin Calcium	Rosuvastatin Calcium	103	31
Trazodone Hcl	Trazodone Hcl	95	32
Trulicity	Dulaglutide	94	18
Albuterol Sulfate Hfa	Albuterol Sulfate	86	31
Gabapentin	Gabapentin	86	26
Escitalopram Oxalate	Escitalopram Oxalate	82	18
Furosemide	Furosemide	81	32
Pioglitazone Hcl	Pioglitazone Hcl	81	22
Allopurinol	Allopurinol	80	23
Eliquis	Apixaban	80	25
Carvedilol	Carvedilol	77	20
Tramadol Hcl	Tramadol Hcl	69	12
Tizanidine Hcl	Tizanidine Hcl	68	13
Montelukast Sodium	Montelukast Sodium	67	20
Meloxicam	Meloxicam	64	17
Sertraline Hcl	Sertraline Hcl	64	20
Fluoxetine Hcl	Fluoxetine Hcl	63	17
Hydralazine Hcl	Hydralazine Hcl	63	19
Alendronate Sodium	Alendronate Sodium	62	19
Citalopram Hbr	Citalopram Hydrobromide	61	17
Fluticasone Propionate	Fluticasone Propionate	61	22
Mounjaro	Tirzepatide	60	11
Glipizide	Glipizide	59	17
Ezetimibe	Ezetimibe	58	17
Duloxetine Hcl	Duloxetine Hcl	53	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	14
Metoprolol Tartrate	Metoprolol Tartrate	46	16
Verapamil Er	Verapamil Hcl	45	11
Bupropion Xl	Bupropion Hcl	42	11
Glipizide Er	Glipizide	42	13
Atenolol	Atenolol	41	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	11
Potassium Chloride	Potassium Chloride	41	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	suppressed
Chlorthalidone	Chlorthalidone	39	16
Paroxetine Hcl	Paroxetine Hcl	39	11
Ropinirole Hcl	Ropinirole Hcl	38	suppressed
Spironolactone	Spironolactone	37	14
Ramipril	Ramipril	36	11
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	12
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Finasteride	Finasteride	32	suppressed
Pregabalin	Pregabalin	32	suppressed
Alprazolam	Alprazolam	31	suppressed
Buspirone Hcl	Buspirone Hcl	30	suppressed
Glimepiride	Glimepiride	30	suppressed
Jardiance	Empagliflozin	29	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	28	suppressed
Prednisone	Prednisone	26	20
Triamcinolone Acetonide	Triamcinolone Acetonide	25	15
Valacyclovir	Valacyclovir Hcl	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Ibuprofen	Ibuprofen	24	13
Famotidine	Famotidine	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	21	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Diclofenac Sodium	Diclofenac Sodium	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Lactulose	Lactulose	20	suppressed
Diazepam	Diazepam	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	18	suppressed
Clobetasol Propionate	Clobetasol Propionate	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Atrovent Hfa	Ipratropium Bromide	14	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	14	suppressed
Valsartan	Valsartan	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Cephalexin	Cephalexin	12	11
Colchicine	Colchicine	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Ozempic	Semaglutide	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Indapamide	Indapamide	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error